Patisiran - Latest Advances

Bioactive lipid-derived nanoparticles for RNA delivery.

Journal: Materials today (Kidlington, England)

Published: August 26, 2026

Guidelines for the management of hereditary ATTR amyloidosis 2026.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: July 09, 2026

The Promise and Pursuit of MicroRNAs for Cancer Treatment.

Journal: Biomolecules

Published: June 18, 2026

Disease-Modifying Therapies for Hereditary Transthyretin Amyloidosis with Polyneuropathy: Current Status and Future Perspectives.

Journal: Neurology and therapy

Published: May 23, 2026

Therapy of amyloidosis: stabilizers and silencers.

Journal: European heart journal supplements : journal of the European Society of Cardiology

Published: May 08, 2026

Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: Current Evidence and Emerging Strategies.

Journal: Journal of clinical medicine research

Published: April 28, 2026

Clinical outcomes with vutrisiran in transthyretin amyloidosis: a systematic review and meta-analysis of randomized trials.

Journal: Global cardiology science & practice

Published: April 19, 2026

Extracellular vesicle-based delivery systems for nucleic acid therapeutics.

Journal: Molecular therapy. Nucleic acids

Published: April 06, 2026

Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Study.

Journal: Medicina (Kaunas, Lithuania)

Published: March 26, 2026

SiaRNA: a siamese neural network with bidirectional cross-attention for pairwise siRNA-mRNA efficacy prediction.

Journal: Frontiers in bioinformatics

Published: March 11, 2026

Real-world effectiveness and clinical predictors of response to first-generation TTR silencers in variant ATTR amyloidosis with polyneuropathy.

Journal: Scientific reports

Published: March 03, 2026

Clinical course after cardiac resynchronization therapy in transthyretin amyloid cardiomyopathy receiving disease-modifying therapy.

Journal: Heart and vessels

Published: February 26, 2026